A new study is shedding more light on the use of the popular GLP-1 weight-loss drugs during early pregnancy. The research looked at what happens when women who have been taking the medication become pregnant, a question that has drawn growing attention as the drugs have become more widely used.
Researchers from Harvard analyzed insurance records from nearly 3,600 pregnancies in order to examine the issue. By drawing on this large set of records, the study aimed to get a clearer picture of whether using the weight-loss drugs around the time of conception was linked to problems in pregnancy.
The study found no clear jump in miscarriage, growth problems or birth defects among the women who had been using the weight-loss drugs. In other words, the data did not show an obvious increase in these outcomes for that group compared with what would otherwise be expected.
Medical experts say that while that is good news, it is not the same as a green light for patients to keep taking the drugs once they know they are pregnant. As they put it, finding nothing is different from proving that nothing is there, and the study itself says more research is needed to understand the risks.
The distinction matters because the absence of a clear signal of harm does not amount to proof that the drugs are safe to use during pregnancy. The findings offer some reassurance to women who conceived while on the medication, but they stop short of recommending that the drugs be continued.
For that reason, the existing guidance remains in place. Manufacturers recommend that women stop taking the medication up to two months before a planned pregnancy, an approach that the new findings do not overturn even as researchers call for further study of the question.